Question 1

What is the dose of MOTS-c?

Accepted Answer

No amount of MOTS-c has been established for a person, and that is not a gap we intend to fill with an estimate. A 2023 review puts it plainly, reporting that no effective method of applying MOTS-c in the clinic has been developed. What exists instead is a handful of animal experiments, each with a separate species, a separate body weight and a separate objective. Rats in a vascular calcification study were injected with MOTS-c at a dose of 5 mg/kg once a day for 4 weeks. Mice in a sepsis study received MOTS-c (20 mg/kg) four hours before model establishment. Dystrophic mice were given long-term repeated administration of MOTS-c (500 μg) over three weeks and then three months. Those figures are experimental parameters attached to particular animals, rather than quantities anybody has tested in a person, and the fourfold difference between the two rodent figures demonstrates how unsettled they remain. We report them as the experimental parameters they are, and we publish no conversion from any of them to a person.

Question 2

Is there a MOTS-c dosage chart?

Accepted Answer

Charts circulate with weekly quantities and week counts beside them, presented as though a single schedule applied universally. Nothing in the published literature supports a chart of that description, because every quantity such a chart requires was assigned to an animal. Set out honestly, the record is four rows deep and not one row is about a person. Rats at 5 mg/kg once a day for 4 weeks. Mice at 20 mg/kg as a single pre-treatment. Dystrophic mice at 500 μg repeated over months, alongside a second compound. The fourth row carries a frequency and no amount at all, because in a gestational diabetes model MOTS-c was administrated daily during pregnancy. Consider what that collection actually represents. Four separate experiments, in two species, pursuing four unrelated outcomes, and nobody designed any of them for comparison against the others. A chart assembled from them would be an invention held together by formatting rather than a summary of established evidence.

Question 3

Is there a MOTS-c dosing protocol or a protocol PDF?

Accepted Answer

No protocol has been published for a person, and the review literature says as much in its own words rather than ours. A 2023 review reports that no effective method of applying MOTS-c in the clinic has been developed. A 2026 review of peptides in sports medicine makes the wider point, observing that many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce. Documents circulating as protocols are therefore not condensed from anything published. A document can be internally tidy and still have nothing behind it, which is harder to spot than an obvious mistake. What the published work does describe is animal protocols, and those have four parts: a species, a weight-based amount, a frequency and a duration. All four are reportable, and we report them. The step from those four to a schedule for a person is one that no paper among the sources has taken in print.

Question 4

How much MOTS-c per day?

Accepted Answer

Daily administration appears twice within the animal literature, and on both occasions without any human counterpart attached. Rats were injected with MOTS-c at a dose of 5 mg/kg once a day for 4 weeks. In a mouse model of gestational diabetes, MOTS-c was administrated daily during pregnancy, and that report gives the frequency without stating an amount. Both of those quantities are calculated against the body weight of a rodent. Converting a per-kilogram animal quantity into a daily equivalent for a person is a step no experiment in this record has validated, and it is not a step we perform. A daily quantity would require an experiment that attempted one in people and measured the consequences. The question has not been asked in print, which is a different situation from having been asked and answered unconvincingly. The first leaves the answer genuinely unknown; the second would at least establish something.

Question 5

How much MOTS-c per week?

Accepted Answer

No weekly schedule has been published for a person, and the animal literature does not operate on a weekly rhythm either. The rat experiment administered the compound once a day for four weeks, which produces a duration measured in weeks rather than a weekly quantity. One experiment does employ a weekly interval, and it repays careful reading, because the weekly figure inside it belongs to a different compound. In dystrophic mice, long-term repeated administration of MOTS-c (500 μg) and PMO at the dose of 12.5 mg/kg/week for 3 weeks followed by 12.5 mg/kg/month for 3 months produced the reported effect on muscle. That weekly quantity attaches to PMO, the second compound, rather than to MOTS-c. So the answer divides into two halves. Nothing weekly has been established for a person, and the solitary weekly quantity in the literature is not describing MOTS-c at all.

Question 6

How much MOTS-c should you inject, and by what route?

Accepted Answer

The first half of that has no answer, because no amount has been established for a person. The second half is reportable, with the standing caveat that it describes animals rather than people. Where a route is stated, it is systemic, meaning the compound reaches the whole body rather than one tissue. A 2022 review describes systemic MOTS-c administration increasing exercise performance by boosting skeletal muscle stress responses and by enhancing metabolic adaptation to exercise. The rat study used a daily injection over four weeks, and the sepsis study gave mice a single administration four hours before the experiment began. What none of that produces is a volume for a syringe. A volume needs a concentration and an amount, and the amount is the half that no study we could find establishes outside an animal experiment, which is where the arithmetic has to stop.

Question 7

What about a 40 mg MOTS-c protocol?

Accepted Answer

No published experiment in these sources has administered 40 mg of MOTS-c, in any species, by any route. The largest quantity anywhere in this literature is 20 mg/kg in mice, which is calculated against body weight rather than a flat amount, so it is not comparable to a number printed on packaging. A flat 40 mg consequently has no published counterpart. That is not a judgement about what 40 mg would accomplish, because no experiment on this page administered it and reported the outcome. The studies behind this page hold no experiment to cite for it, and a quantity with no experiment behind it is not a larger version of a quantity that has one. Where 40 mg does appear is on packaging, as a weight of powder sitting inside a vial. Vial size is a packaging fact rather than a protocol, and it describes the contents of the glass instead of anything anybody has tested. The two are confused constantly, which is precisely why this question keeps returning.

Question 8

How much BAC water do you mix with MOTS-c?

Accepted Answer

Reconstitution is arithmetic, and it works identically for every powder. A 10 mg vial holds 10,000 micrograms before anything is added, so 1 mL of bacteriostatic water leaves the concentration at 10,000 micrograms per mL, 2 mL leaves it at 5,000 micrograms per mL, and 5 mL leaves it at 2,000 micrograms per mL. A 5 mg vial holds 5,000 micrograms and divides exactly the same way. The diluent volume sets the concentration and alters nothing else. It does not change how much compound is sitting in the glass, and it cannot settle the second half of the sum, which is the amount anybody would eventually draw. For MOTS-c that second half is missing. A 2023 review reports that no effective method of applying MOTS-c in the clinic has been developed, so the arithmetic stops at a concentration rather than carrying on into a volume on a syringe.

Question 9

How many doses are in a 10 mg vial of MOTS-c?

Accepted Answer

Two questions sit inside that one, and only one of them can be answered. How long reconstituted material holds up as chemistry is not addressed in the published work on this compound, so there is no storage interval to give. How many draws a vial contains is division, and the division needs a number no study among the research behind this page has published. A 10 mg vial holds 10,000 micrograms however it is diluted, so the count depends entirely on the amount per draw. The animal studies expressed their amounts per kilogram of body weight, a unit that appears on no syringe and does not carry across species. Only one published figure is not weight-scaled. Dystrophic mice received long-term repeated administration of MOTS-c (500 μg) alongside a second compound, in a muscular dystrophy experiment. Lifting that out and dividing a vial by it would be arithmetic performed on a borrowed number rather than a calculation anyone could stand behind.

Question 10

Should you cycle off MOTS-c, and how often?

Accepted Answer

No study among the research behind this page has tested a cycle, a break or a taper, so there is no interval to report and no off-period anybody has measured. The durations that do exist belong to experiments rather than to schedules, and every one concluded when its experiment concluded: four weeks of daily injection in rats, a single administration four hours preceding a sepsis model in mice, and three weeks followed by three months in dystrophic mice. None of those experiments was designed with an off-period inside it. A course running for the duration of a study is not a cycle, and interpreting it as one imports a structure the experiment never possessed. A further complication makes the question awkward here. MOTS-c is something the body already produces, and a 2023 review notes that plasma contains the protein at a level which diminishes with age. What that implies about the logic of cycling has not been established in print, and we would be speculating to suggest otherwise.

Question 11

Has any study given MOTS-c to a person?

Accepted Answer

Not in the published work. Every study with an amount in it used animals, and the human studies measure something else: how much MOTS-c a person already has. A 2026 muscle study did both at once. It ran its tests in two mouse strains, then turned to people: during one-legged knee extensor exercise in humans, MOTS-c rose in the fluid around the muscle while nothing changed across the working leg. A 2025 heart-surgery study tracked the level in blood after bypass, and found that a rise within 24 hours beat older markers at predicting a lung complication. Both measured a level rather than an amount anyone was given. Three entries sit on the trial registry, and two of them measure levels as well. The third is a Phase 2 study of MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity, listed as recruiting, and it has published nothing so far.

Question 12

How much does MOTS-c cost?

Accepted Answer

No source among the research behind this page reports a price for MOTS-c, and none would be expected to. Price is a market fact rather than a research finding, and the literature on this compound is almost entirely animal work. What the literature does explain is why no approved price exists. A 2023 review reports that no effective method of applying MOTS-c in the clinic has been developed, and a 2026 review of peptides in sports medicine places MOTS-c among the unapproved compounds, noting that rigorous human safety data are scarce. An unapproved compound has no list price, no pharmacy price and no reimbursement figure to report. Figures quoted elsewhere come from sellers, and we have no way to check any of them. What we can describe is what a price would be buying: a vial of powder whose identity, strength and sterility no analysis among the research behind this page has measured.

Question 13

Why do the published amounts vary so much?

Accepted Answer

Because no two of these experiments were asking the same question. The rat study set out to evaluate whether MOTS-c, a novel mitochondria-related 16-aa peptide, can reduce vitamin D3 and nicotine-induced VC in rats, where VC means hardening of the blood vessels. The mouse study explored the protective effects of MOTS-c against brain injury in mice with LPS-induced sepsis. The third was using MOTS-c to help a second compound get into dystrophic muscle. Different outcomes call for different exposures, and an amount chosen to keep a mouse alive through sepsis has nothing in common with one chosen to shift a calcification score over four weeks. A second reason sits underneath all of it. A 2025 review groups MOTS-c with exercise mimetics, and a 2022 review describes exogenous MOTS-c stimulating thermogenesis in subcutaneous white adipose tissues. A compound studied across that many systems collects amounts from all of them, and not one of those amounts was chosen for a person.

Experiment	Animal	Amount studied	Schedule
Vascular calcification	Rats	5 mg/kg	Once a day for 4 weeks
Sepsis	Mice	20 mg/kg	Four hours before model establishment
Muscular dystrophy	Dystrophic mice	500 μg	Repeated over three weeks, then three months

MOTS-c protocols in the published literature